SG11201504769WA - Pharmaceutical formulation of n- [5- [2-(3,5-dimethoxyphenyl) ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl] benzamide - Google Patents

Pharmaceutical formulation of n- [5- [2-(3,5-dimethoxyphenyl) ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl] benzamide

Info

Publication number
SG11201504769WA
SG11201504769WA SG11201504769WA SG11201504769WA SG11201504769WA SG 11201504769W A SG11201504769W A SG 11201504769WA SG 11201504769W A SG11201504769W A SG 11201504769WA SG 11201504769W A SG11201504769W A SG 11201504769WA SG 11201504769W A SG11201504769W A SG 11201504769WA
Authority
SG
Singapore
Prior art keywords
dimethylpiperazin
dimethoxyphenyl
pyrazol
benzamide
ethyl
Prior art date
Application number
SG11201504769WA
Other languages
English (en)
Inventor
Noel Alan Weldon Baker
Alpesh Mistry
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49998566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201504769W(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SG11201504769WA publication Critical patent/SG11201504769WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201504769WA 2012-12-21 2013-12-19 Pharmaceutical formulation of n- [5- [2-(3,5-dimethoxyphenyl) ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl] benzamide SG11201504769WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261740520P 2012-12-21 2012-12-21
PCT/GB2013/053356 WO2014096828A1 (en) 2012-12-21 2013-12-19 Pharmaceutical formulation of n- [5- [2-(3,5-dimethoxyphenyl) ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl] benzamide

Publications (1)

Publication Number Publication Date
SG11201504769WA true SG11201504769WA (en) 2015-07-30

Family

ID=49998566

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201504769WA SG11201504769WA (en) 2012-12-21 2013-12-19 Pharmaceutical formulation of n- [5- [2-(3,5-dimethoxyphenyl) ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl] benzamide

Country Status (26)

Country Link
US (2) US20140179712A1 (zh)
EP (1) EP2934494B1 (zh)
JP (1) JP6328138B2 (zh)
KR (1) KR20150096787A (zh)
CN (1) CN104853750B (zh)
AR (1) AR094203A1 (zh)
AU (1) AU2013366023B2 (zh)
BR (1) BR112015014200A2 (zh)
CA (1) CA2893480C (zh)
CL (1) CL2015001786A1 (zh)
CR (1) CR20150320A (zh)
DO (1) DOP2015000127A (zh)
ES (1) ES2742400T3 (zh)
HK (1) HK1212229A1 (zh)
IL (1) IL239521A0 (zh)
MX (1) MX368670B (zh)
NI (1) NI201500087A (zh)
PE (1) PE20151418A1 (zh)
PH (1) PH12015501389A1 (zh)
RU (1) RU2674978C2 (zh)
SG (1) SG11201504769WA (zh)
TW (1) TWI651085B (zh)
UA (1) UA115342C2 (zh)
UY (1) UY35244A (zh)
WO (1) WO2014096828A1 (zh)
ZA (1) ZA201505197B (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide
WO2024031226A1 (zh) * 2022-08-08 2024-02-15 无锡和誉生物医药科技有限公司 Fgfr抑制剂的药物组合物、多晶型物及其在药学上的应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB843940A (en) 1955-09-27 1960-08-10 Kodak Ltd Method of processing photographic silver halide emulsions containing colour couplers
BE667399A (zh) 1964-07-30 1965-11-16
JPS57150846A (en) 1981-03-13 1982-09-17 Konishiroku Photo Ind Co Ltd Photographic element
JPS63133152A (ja) 1986-11-26 1988-06-04 Konica Corp 新規なマゼンタカプラ−を含有するハロゲン化銀写真感光材料
JPH0467645A (ja) 1990-07-09 1992-03-03 Nec Kyushu Ltd バーンイン装置
US5292520A (en) * 1990-09-13 1994-03-08 Akzo N.V. Stabilized solid pharmaceutical composition containing acid addition salts of a basic drug and an alkaline stabilizer
JP2890065B2 (ja) 1990-11-10 1999-05-10 コニカ株式会社 ハロゲン化銀写真感光材料
JPH04184437A (ja) 1990-11-20 1992-07-01 Fuji Photo Film Co Ltd カラー画像形成方法及びハロゲン化銀カラー写真感光材料
JPH04292322A (ja) 1991-03-19 1992-10-16 Fujitsu Ltd ラック給排装置
JPH0511414A (ja) 1991-07-02 1993-01-22 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
SK44894A3 (en) 1991-10-18 1995-04-12 Monsanto Co Trisubstituted aromatic compounds, method of their preparation and fungicidal agents
AU3934693A (en) 1992-03-26 1993-10-21 Dowelanco N-heterocyclic nitro anilines as fungicides
HRP921338B1 (en) 1992-10-02 2002-04-30 Monsanto Co Fungicides for the control of take-all disease of plants
TW240217B (zh) 1992-12-30 1995-02-11 Glaxo Group Ltd
JP3156026B2 (ja) 1993-12-27 2001-04-16 株式会社大塚製薬工場 ホスホン酸ジエステル誘導体
CA2203517A1 (en) 1994-11-10 1996-05-23 Alan M. Laibelman Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases
FR2745500B1 (fr) 1996-03-04 1998-04-03 Synthelabo Formulations pharmaceutiques a liberation prolongee contenant de la mizolastine
CZ225699A3 (cs) 1996-12-23 2000-09-13 Du Pont Pharmaceuticals Company Dusíkaté heteroaromatické sloučeniny jako inhibitory faktoru Xa
CA2302438A1 (en) 1997-05-19 1998-11-26 Sugen, Inc. Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders
US6087381A (en) 1997-05-22 2000-07-11 G. D. Searle & Company Pyrazole derivatives as p38 kinase inhibitors
US6271237B1 (en) 1997-12-22 2001-08-07 Dupont Pharmaceuticals Company Nitrogen containing heteromatics with ortho-substituted P1s as factor Xa inhabitors
JP3310226B2 (ja) 1998-10-16 2002-08-05 松下電器産業株式会社 音声合成方法および装置
GB9823103D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
NZ514095A (en) 1999-02-10 2001-09-28 Welfide Corp Amide compounds and medicinal use thereof
WO2000049001A2 (en) 1999-02-16 2000-08-24 E.I. Du Pont De Nemours And Company Phenoxy-, phenylthio-, phenylamino-, benzyloxy-, benzylthio- or benzylaminopyrimidine insectidices and acaricides
CN1373662A (zh) 1999-08-12 2002-10-09 法玛西雅意大利公司 3(5)－氨基－吡唑衍生物、其制备方法及其用作抗肿瘤剂的用途
AU6909600A (en) 1999-08-13 2001-03-13 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
US6552008B1 (en) 1999-09-24 2003-04-22 Smithkline Beecham Corporation Thrombopoietin mimetics
US20050209297A1 (en) 2000-08-31 2005-09-22 Pfizer Inc Pyrazole derivatives
KR20030030029A (ko) 2000-09-22 2003-04-16 니혼노야쿠가부시키가이샤 Ｎ-(4-피라졸릴)아미드 유도체 및 농원예용 약제 그리고그 사용방법
AU2002222683B9 (en) 2000-12-18 2021-12-23 Institute Of Medicinal Molecular Design, Inc Inflammatory cytokine release inhibitor
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
AU2002305260A1 (en) 2001-04-27 2002-11-11 Vertex Pharmaceuticals Incorporated Pyrazole derived kinase inhibitors
IS1935B (is) * 2002-03-19 2004-06-16 Actavis Group Hf. Fósínópríl lyfjasamsetning
WO2003103648A1 (ja) 2002-06-05 2003-12-18 株式会社医薬分子設計研究所 糖尿病治療薬
TW200407112A (en) 2002-06-05 2004-05-16 Inst Med Molecular Design Inc Immunity-related protein kinase inhibitors
JP4660674B2 (ja) 2002-06-06 2011-03-30 株式会社医薬分子設計研究所 抗アレルギー薬
AU2003252478A1 (en) 2002-07-10 2004-02-02 Ono Pharmaceutical Co., Ltd. Ccr4 antagonist and medicinal use thereof
US7176198B2 (en) 2002-08-01 2007-02-13 Pfizer Inc. 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease
DE602004028907D1 (de) 2003-02-06 2010-10-14 Bristol Myers Squibb Co Als kinaseinhibitoren geeignete verbindungen auf thiazolylbasis
US20040220170A1 (en) 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
RS20050789A (sr) 2003-05-01 2008-04-04 Bristol-Myers Squibb Company, Aril-supstituisana jedinjenja pirazol-amida pogodna za primenu kao inhibitori kinaze
US7115359B2 (en) 2003-07-25 2006-10-03 Konica Minolta Medical & Graphic, Inc. Photothermographic material
ATE413395T1 (de) 2003-08-21 2008-11-15 Osi Pharm Inc N-substituierte pyrazolyl-amidyl-benzimidazolyl-c-kit-inhibitor n
US7432271B2 (en) 2003-09-02 2008-10-07 Bristol-Myers Squibb Company Pyrazolyl inhibitors of 15-lipoxygenase
WO2005048953A2 (en) 2003-11-13 2005-06-02 Ambit Biosciences Corporation Amide derivatives as kinase modulators
ES2347152T3 (es) 2003-11-26 2010-10-26 Pfizer Products Inc. Derivados de aminopirazol como inhibidores de gsk-3.
US7652146B2 (en) 2004-02-06 2010-01-26 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors
GB2411355B (en) * 2004-02-27 2006-02-22 Niche Generics Ltd Pharmaceutical composition
US7253204B2 (en) 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
US7531556B2 (en) 2004-04-28 2009-05-12 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
CN101273023A (zh) 2005-08-02 2008-09-24 Irm责任有限公司 作为蛋白激酶抑制剂的5-取代的噻唑-2-基氨基化合物和组合物
EP1945190A1 (en) * 2005-09-22 2008-07-23 Swissco Devcelopment AG Effervescent metformin composition and tablets and granules made therefrom
IS2385B (is) * 2006-02-10 2008-07-15 Actavis Group Hf. Klópidógrel bísúlfat lyfjasamsetningar
US7737149B2 (en) * 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
PL386051A1 (pl) * 2008-09-09 2010-03-15 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Stabilna doustna kompozycja farmaceutyczna zawierająca farmaceutycznie dopuszczalną sól kwsu [(E)-7-[4-(4-fluorofenylo)-6-izopropylo-2-[metylo(metylosulfonylo)amino]pirymidyn-5-ylo] (3R,5S)-3,5-dihydroksyhept-6-enowego
SG10201401712QA (en) * 2009-04-24 2014-08-28 Iceutica Pty Ltd Method for the production of commercial nanoparticle and microparticle powders
WO2010137855A2 (en) * 2009-05-27 2010-12-02 Dasan Medichem Co., Ltd. Multi-layer tablet comprising effervescent layer
EP2464340A2 (en) * 2009-08-12 2012-06-20 Valeant International (Barbados) SRL Pharmaceutical compositions with tetrabenazine
WO2012052757A1 (en) * 2010-10-20 2012-04-26 Astrazeneca Ab Tumour phenotype patient selection method
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide

Also Published As

Publication number Publication date
PE20151418A1 (es) 2015-10-21
TWI651085B (zh) 2019-02-21
MX368670B (es) 2019-10-10
JP2016503782A (ja) 2016-02-08
TW201431553A (zh) 2014-08-16
CL2015001786A1 (es) 2015-08-14
CA2893480A1 (en) 2014-06-26
JP6328138B2 (ja) 2018-05-23
EP2934494A1 (en) 2015-10-28
CR20150320A (es) 2015-09-11
EP2934494B1 (en) 2019-06-12
RU2674978C2 (ru) 2018-12-14
PH12015501389A1 (en) 2015-09-02
US10420764B2 (en) 2019-09-24
CN104853750B (zh) 2018-06-26
ES2742400T3 (es) 2020-02-14
IL239521A0 (en) 2015-08-31
KR20150096787A (ko) 2015-08-25
ZA201505197B (en) 2017-07-26
US20170119759A1 (en) 2017-05-04
NI201500087A (es) 2016-02-16
CN104853750A (zh) 2015-08-19
CA2893480C (en) 2021-01-12
RU2015126345A (ru) 2017-01-30
DOP2015000127A (es) 2015-07-31
US20140179712A1 (en) 2014-06-26
AR094203A1 (es) 2015-07-15
WO2014096828A1 (en) 2014-06-26
AU2013366023A1 (en) 2015-06-18
HK1212229A1 (zh) 2016-06-10
MX2015008067A (es) 2016-04-25
UY35244A (es) 2014-01-31
UA115342C2 (uk) 2017-10-25
AU2013366023B2 (en) 2016-10-27
BR112015014200A2 (pt) 2017-07-11

Similar Documents

Publication Publication Date Title
IL260297A (en) Process for preparing n-[5-(5,3-difluoro-benzyl)-h1-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino )–benzamide
IL244943B (en) History of n-[3-(5-oxy-6-amino-pyrimidin-4-yl)phenyl]benzamide and pharmaceutical preparations that include them
IL232462A (en) Annals of 2- (1, 2, 3-triazole-2-ram) benzamide and 3- (3,2,1-triazole-2-ram) picolinamide, containing and using pharmaceutical preparations
PL2773335T3 (pl) Amidy kwasu szczawiowego jako inhibitory neprylizyny, ich kompozycje farmaceutyczne i otrzymywanie
IL233154A (en) Compounds, pharmaceuticals containing them and their uses
IL220863A (en) Oxazole derivatives of kinase inhibitors, medicinal preparations containing them and their uses
IL232035A (en) These heterocyclic compounds, these compounds as a medicine and a pharmaceutical composition containing them
SI2389378T1 (sl) Priprava in terapevtske uporabe (2s,3r)-n-2-((3-piridinil)metil)-1- azabiciklo(2.2.2)okt-3-il)-3,5-difluorobenzamida
IL233602A (en) The history of benzamide, their preparation and their pharmaceutical preparations
HK1188791A1 (zh) 新型八氫噻吩並喹啉衍生物、包含所述衍生物的藥物組合物及它們的用途
HK1206346A1 (zh) 作為雄激素受體拮抗劑的 喹啉- -基氧基 環己基 甲基 芳基甲酰胺、其製法及其用作藥品的用途
ZA201301385B (en) Therapeutic uses of 1-[2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
HK1212229A1 (zh) -二甲氧基苯基 乙基 -吡唑- -基 -二甲基哌嗪- -基 苯甲酰胺的醫藥配製品
SMT201600096B (it) Composizione farmaceutica comprendente (s)-2-(2oxopirrolidin-1-il)butanamide
EP2738174A4 (en) NOVEL PYRIMIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT